Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2006

01-10-2006 | Original Article

Incidental Small Ampullary Somatostatinoma Treated with Ampullectomy 2 Years After Diagnosis

Authors: G. Guercioni, C. Marmorale, W. Siquini, M. Fianchini, A. Fianchini, E. Landi

Published in: Digestive Diseases and Sciences | Issue 10/2006

Login to get access

Abstract

Somatostatinomas are rare tumors; ampullary somatostatinomas are very rare. We report a case of a small pure somatostatin-producing neuroendocrine tumor of ampulla of Vater in a 54-year-old woman with neither neurofibromatosis nor somatostatinoma syndrome, “incidentally” discovered during an abdominal computed tomography. The patient initially refused other adjunctive exams but after 2 years she was admitted, presenting with itch, night sweats, severe fatigue, and unintentional weight loss. The size of the tumor (1.5 cm) and the other radiologic findings had not changed since the abdominal CT scan 2 years before. The somatostatin, gastrin, glucagons, serotonin, vasoactive intestinal peptide, dopamine, norepinephrine, epinephrine, and calcitonin plasma levels were normal. ERCP-obtained biopsies revealed a neuroendocrine tumor with psammoma bodies; immunohistochemical profile was positive for chromogranin and somatostatin. The patient underwent surgery; intraoperative histologic examination of lymph nodes sampling of perihepatic and periduodenal lymph nodes was negative for metastasis. We performed, therefore, a transduodenal ampullectomy. The patient continues to do well at 3 years’ follow-up with no evidence of local or distance recurrence of disease.
Literature
1.
go back to reference Larsson LI, Hirsch MA, Holst JJ, Ingemansson S, Kuhl C, Jensen SL, Lundqvist G, Rehfeld JF, Schwartz TW (1977) Pancreatic somatostatinoma. Clinical features and physiological implications. Lancet 1(8013):666–668PubMedCrossRef Larsson LI, Hirsch MA, Holst JJ, Ingemansson S, Kuhl C, Jensen SL, Lundqvist G, Rehfeld JF, Schwartz TW (1977) Pancreatic somatostatinoma. Clinical features and physiological implications. Lancet 1(8013):666–668PubMedCrossRef
2.
go back to reference Ganda OP, Weir GC, Soeldner JS, Legg MA, Chick WL, Patel YC, Ebeid AM, Gabbay KH, Reichlin S (1977) “Somatostatinoma”: a somatostatin-containing tumor of the endocrine pancreas. N Engl J Med 296:963–967PubMedCrossRef Ganda OP, Weir GC, Soeldner JS, Legg MA, Chick WL, Patel YC, Ebeid AM, Gabbay KH, Reichlin S (1977) “Somatostatinoma”: a somatostatin-containing tumor of the endocrine pancreas. N Engl J Med 296:963–967PubMedCrossRef
3.
go back to reference House MG, Yeo CJ, Schulick MD (2002) Periampullary pancreatic somatostatinoma. Ann Surg Oncol 9:869–874PubMed House MG, Yeo CJ, Schulick MD (2002) Periampullary pancreatic somatostatinoma. Ann Surg Oncol 9:869–874PubMed
4.
go back to reference Kaneko H, Yanaihara N, Ito S, Kusumoto Y, Fujita T, Ishikawa S, Sumida T, Sekiya M (1979) Somatostatinoma of the duodenum. Cancer 44:2273–2279PubMedCrossRef Kaneko H, Yanaihara N, Ito S, Kusumoto Y, Fujita T, Ishikawa S, Sumida T, Sekiya M (1979) Somatostatinoma of the duodenum. Cancer 44:2273–2279PubMedCrossRef
5.
go back to reference Malone MJ, Silverman ML, Braasch JW, Jin GL, Dayal Y (1985) Early somatostatinoma of the papilla of the duct of Santorini. Arch Surg 120:1381–1383PubMed Malone MJ, Silverman ML, Braasch JW, Jin GL, Dayal Y (1985) Early somatostatinoma of the papilla of the duct of Santorini. Arch Surg 120:1381–1383PubMed
6.
go back to reference Harris GJ, Tio F, Cruz AB Jr (1987) Somatostatinoma: a case report and review of the literature. J Surg Oncol 36:8–16PubMed Harris GJ, Tio F, Cruz AB Jr (1987) Somatostatinoma: a case report and review of the literature. J Surg Oncol 36:8–16PubMed
7.
go back to reference Goodman ZD, Albores-Saavedra J, Lundblad DM (1984) Somatostatinoma of the cystic duct. Cancer 53:498–502PubMedCrossRef Goodman ZD, Albores-Saavedra J, Lundblad DM (1984) Somatostatinoma of the cystic duct. Cancer 53:498–502PubMedCrossRef
8.
go back to reference Kitagawa M, Hayakawa T, Kondo T, Shibata T, Sakai Y, Ono H, Kiriyama S, Yokoi T (1989) Somatostatinoma of the rectum. Am J Gastroenterol 84:1452–1455PubMed Kitagawa M, Hayakawa T, Kondo T, Shibata T, Sakai Y, Ono H, Kiriyama S, Yokoi T (1989) Somatostatinoma of the rectum. Am J Gastroenterol 84:1452–1455PubMed
9.
go back to reference Kelly TR (1994) Somatostatinoma. Prob Gen Surg 11:99–119 Kelly TR (1994) Somatostatinoma. Prob Gen Surg 11:99–119
10.
go back to reference O’Brien TD, Chejfec G, Prinz RA (1993) Clinical features of duodenal somatostatinomas. Surgery 114:1144–1147PubMed O’Brien TD, Chejfec G, Prinz RA (1993) Clinical features of duodenal somatostatinomas. Surgery 114:1144–1147PubMed
11.
go back to reference Udelsman R, Yeo CJ, Hruban RH, Pitt HA, Niederhuber JE, Coleman J, Cameron JL (1993) Pancreaticoduodenectomy for selected pancreatic endocrine tumors. Surg Gynecol Obstet 177:269–278PubMed Udelsman R, Yeo CJ, Hruban RH, Pitt HA, Niederhuber JE, Coleman J, Cameron JL (1993) Pancreaticoduodenectomy for selected pancreatic endocrine tumors. Surg Gynecol Obstet 177:269–278PubMed
12.
go back to reference Green BT, Rockey DC (2001) Duodenal somatostatinoma presenting with complete somatostatinoma syndrome. J Clin Gastroenterol 33:415–417PubMedCrossRef Green BT, Rockey DC (2001) Duodenal somatostatinoma presenting with complete somatostatinoma syndrome. J Clin Gastroenterol 33:415–417PubMedCrossRef
13.
go back to reference Saifuddin T, Linder C, Banerjee B (1999) Duodenal somatostatinoma presenting as upper gastrointestinal bleeding. Am J Gastroenterol 94:1405–1408PubMedCrossRef Saifuddin T, Linder C, Banerjee B (1999) Duodenal somatostatinoma presenting as upper gastrointestinal bleeding. Am J Gastroenterol 94:1405–1408PubMedCrossRef
14.
go back to reference Ranaldi R, Bearzi I, Cinti S, Suraci V (1988) Ampullary somatostatinoma. An immunohistochemical and ultrastructural study. Path Res Pract 183:8–16PubMed Ranaldi R, Bearzi I, Cinti S, Suraci V (1988) Ampullary somatostatinoma. An immunohistochemical and ultrastructural study. Path Res Pract 183:8–16PubMed
15.
go back to reference Krejs GJ, Orei L, Conlon JM, et al. (1979) Somatostatinoma syndrome: biochemical morphological and clinical features. N Engl J Med 301:285–293PubMedCrossRef Krejs GJ, Orei L, Conlon JM, et al. (1979) Somatostatinoma syndrome: biochemical morphological and clinical features. N Engl J Med 301:285–293PubMedCrossRef
16.
go back to reference Hamissa S, Rahmouni A, Couffin C, Wolkenstein P (1999) CT detection of an ampullary somatostatinoma in a patient with von Recklinghausen’s disease. Am J Roentgenol 173:503–504 Hamissa S, Rahmouni A, Couffin C, Wolkenstein P (1999) CT detection of an ampullary somatostatinoma in a patient with von Recklinghausen’s disease. Am J Roentgenol 173:503–504
17.
go back to reference Jensen SL, Christiansen LA, Oxholm A et al. (1984) Duodenal somatostatinoma. Br J Surg 71:159PubMed Jensen SL, Christiansen LA, Oxholm A et al. (1984) Duodenal somatostatinoma. Br J Surg 71:159PubMed
18.
go back to reference Mao C, Shah A, Hanson DJ, et al. (1995) Von Recklinghausen’s disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. J Surg Oncol 59:67–73PubMed Mao C, Shah A, Hanson DJ, et al. (1995) Von Recklinghausen’s disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. J Surg Oncol 59:67–73PubMed
19.
go back to reference Vinik AL, Strodel WE, Eckhauser FE (1987) Somatostatinomas, vipomas and neurotensinomas. Semin Oncol 14:263–281PubMed Vinik AL, Strodel WE, Eckhauser FE (1987) Somatostatinomas, vipomas and neurotensinomas. Semin Oncol 14:263–281PubMed
20.
go back to reference Ferenczy A, Talens M, Zonghby M, Hussain SS (1977) Ultrastructural studies on the morphogenesis of psammoma bodies in ovarian serous neoplasia. Cancer 39:2451–2459PubMedCrossRef Ferenczy A, Talens M, Zonghby M, Hussain SS (1977) Ultrastructural studies on the morphogenesis of psammoma bodies in ovarian serous neoplasia. Cancer 39:2451–2459PubMedCrossRef
21.
go back to reference Rios A, Fernandez JA, Rodriguez JM, Lujan JA, Martinez E, Parrilla P (2001) Massive upper gastrointestinal bleeding as a manifestation of somatostatinoma of the ampulla of Vater. Dig Dis Sci 46:2162–2165PubMedCrossRef Rios A, Fernandez JA, Rodriguez JM, Lujan JA, Martinez E, Parrilla P (2001) Massive upper gastrointestinal bleeding as a manifestation of somatostatinoma of the ampulla of Vater. Dig Dis Sci 46:2162–2165PubMedCrossRef
22.
go back to reference Taccagni GL, Carlucci M, Sironi M, et al. (1986) Duodenal somatostatinoma with psammoma bodies: an immunohistochemical and ultrastructural study. Am J Gastroenterol 81:33–37PubMed Taccagni GL, Carlucci M, Sironi M, et al. (1986) Duodenal somatostatinoma with psammoma bodies: an immunohistochemical and ultrastructural study. Am J Gastroenterol 81:33–37PubMed
23.
go back to reference Soga J, Yakuwa Y (1999) Somatostatinoma inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 18:13–22PubMed Soga J, Yakuwa Y (1999) Somatostatinoma inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 18:13–22PubMed
24.
go back to reference Delcore R, Friesen SR (1994) Gastrointestinal neuroendocrine tumors. J Am Coll Surg 178:187–211PubMed Delcore R, Friesen SR (1994) Gastrointestinal neuroendocrine tumors. J Am Coll Surg 178:187–211PubMed
25.
go back to reference Tanaka S, Yamasaki S, Matsushita H, Ozawa Y, Kurosaki A, Takeuchi K, Hoshihara T, Watanabe G, Kawaminami K (2000) Duodenal somatostatinoma: A casa report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathol Intl 50:146–152CrossRef Tanaka S, Yamasaki S, Matsushita H, Ozawa Y, Kurosaki A, Takeuchi K, Hoshihara T, Watanabe G, Kawaminami K (2000) Duodenal somatostatinoma: A casa report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathol Intl 50:146–152CrossRef
26.
go back to reference Reubi JC (1995) Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 36:1825–1835PubMed Reubi JC (1995) Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 36:1825–1835PubMed
27.
go back to reference Madeira I, Terris B, Voss M, et al. (1998) Prognostic factors with endocrine tumors of the duodenopancreatic area. Gut 43:422–427PubMedCrossRef Madeira I, Terris B, Voss M, et al. (1998) Prognostic factors with endocrine tumors of the duodenopancreatic area. Gut 43:422–427PubMedCrossRef
28.
go back to reference Moertel CG, Lefkopoulo M, Lipsitz S (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523PubMedCrossRef Moertel CG, Lefkopoulo M, Lipsitz S (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523PubMedCrossRef
29.
go back to reference Brentjens R, Saltz L (2001) Islet cell tumors of the pancreas: the medical oncologist’s perspective. Surg Clin North Am 81:527–542PubMedCrossRef Brentjens R, Saltz L (2001) Islet cell tumors of the pancreas: the medical oncologist’s perspective. Surg Clin North Am 81:527–542PubMedCrossRef
Metadata
Title
Incidental Small Ampullary Somatostatinoma Treated with Ampullectomy 2 Years After Diagnosis
Authors
G. Guercioni
C. Marmorale
W. Siquini
M. Fianchini
A. Fianchini
E. Landi
Publication date
01-10-2006
Published in
Digestive Diseases and Sciences / Issue 10/2006
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9222-1

Other articles of this Issue 10/2006

Digestive Diseases and Sciences 10/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine